DOYLESTOWN, Pa., June 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- The Quigley Corporation (Nasdaq: QGLY) announced today it has obtained the results from a series of In-Vivo (animal model) inflammation studies conducted at a leading university research center of a potential broad-spectrum anti-inflammatory, all natural, botanical compound (QR440) developed by its wholly owned subsidiary, Quigley Pharma.
QR440 was initially tested to determine its effect upon Delayed-Type- Hypersensitivity (DTH). DTH is Th-1 type T cell response that initiates immune-mediated inflammation. It was found DTH responses were significantly reduced in QR440-treated mice at 24 hours post challenge.
A second study tested the compound's effect on granulocyte migration. An anaerobic bacterial growth medium was introduced into the mice to induce the mobilization of granulocytes. Compound QR440 significantly inhibited the recruitment of granulocytes into the site of inflammation.
These studies demonstrate that QR440 has a significant effect on both sterile and immune mediated inflammation without resorting to large doses.
According to Quigley Pharma's Chief Operating Officer, Dr. Richard Rosenbloom, "We continue to be very pleased with the progress of QR440. There is significant need for safe and effective therapies for patients with rheumatoid arthritis and other inflammatory disorders. This study has defined some of the mechanisms of action. However, continued research is required to confirm if this broad spectrum botanical compound can improve on the safety and efficacy profiles of the current class of drugs used to treat these conditions."
The Quigley Corporation's President and CEO, Guy Quigley stated, "The concerns raised about Cyclo-oxigenase-2 inhibitors and their safety, particularly for heart patients has lead to our increased interest in finding a safe anti-inflammatory to relieve pain and other symptoms through the use of naturally-derived compounds. We are excited about the potential to enter this category that could help millions of people worldwide."
The Quigley Corporation is the leading developer and marketer of diversified health products. The company's proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned compound to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. In October of 2004, The Company, through its wholly owned subsidiary, Quigley Manufacturing, Inc. acquired two FDA approved facilities to manufacture its COLD-EEZE(R) branded lozenges. InnerLight Inc., a wholly owned subsidiary, was formed in December 2000 for the purpose of introducing new products to the marketplace through a network of independent distributors. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.